Globus Medical (NYSE:GMED) Issues Quarterly Earnings Results

Globus Medical (NYSE:GMED) announced its quarterly earnings data on Thursday. The medical device company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.20 by $0.03, FiscalAI reports. Globus Medical had a return on equity of 14.51% and a net margin of 17.76%. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. During the same quarter last year, the firm posted $1.18 earnings per share. The company’s revenue for the quarter was down .7% on a year-over-year basis. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Q3 revenue declined 0.7% to $763.7 million, as 3% growth in the base business excluding Nevro was offset by Nevro’s 25.7% decline. U.S. Spine grew 2%, held back by delayed product launches and lower-than-expected contributions from competitive recruiting.
• Globus lowered its 2026 revenue outlook to $3.09 billion from $3.18 billion–$3.22 billion, citing Nevro weakness and limited contribution from new products this year. It reiterated non-GAAP EPS guidance of $4.95–$5.05.
• Profitability and cash generation improved despite the revenue decline: non-GAAP EPS rose 4% to $1.23, adjusted gross margin expanded 140 basis points to 69.5%, and free cash flow reached a record $225 million.
• Management expects new spine products—including SCRIPT, XLIF Prone, and eIQ—and greater robot and navigation pull-through to support growth in 2027 and beyond. Enabling Technologies revenue grew 24% in Q3, while deployed units rose 45% year over year.
• The board authorized an additional $500 million share-repurchase program; Globus repurchased $142.9 million of shares in Q3. Management also expects continued margin improvement, while noting that higher R&D investment is planned.

Globus Medical Stock Performance

Shares of GMED traded down $10.77 on Friday, hitting $70.67. 9,272,194 shares of the stock traded hands, compared to its average volume of 1,418,585. The company has a market capitalization of $9.49 billion, a PE ratio of 14.30, a P/E/G ratio of 1.14 and a beta of 0.98. The business has a 50 day simple moving average of $77.20 and a 200 day simple moving average of $83.18. Globus Medical has a one year low of $70.39 and a one year high of $101.40.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GMED shares. UBS Group initiated coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research report on Friday. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a research report on Friday. Wall Street Zen lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Needham & Company LLC cut their price objective on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Insider Activity at Globus Medical

In related news, Director James R. Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director owned 25,000 shares in the company, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 60,000 shares of company stock valued at $4,838,400. 18.38% of the stock is owned by corporate insiders.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.